NASDAQ:SOPH

SOPHiA GENETICS (SOPH) Stock Forecast, Price & News

$2.45

+0.03 (+1.24%)

(As of 03:59 PM ET)

Compare

Today's Range: $2.41
▼
$2.55
50-Day Range: $2.30
▼
$4.24
52-Week Range: $1.68
▼
$5.77

Volume: 13,618 shs
Average Volume: 83,839 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.33

SOPHiA GENETICS MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 155.4% Upside
$6.33 Price Target
Short Interest: Healthy
0.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.20) to ($0.88) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
SOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.33, SOPHiA GENETICS has a forecasted upside of 155.4% from its current price of $2.48.
Amount of Analyst Coverage
SOPHiA GENETICS has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.06% of the float of SOPHiA GENETICS has been sold short.
Short Interest Ratio / Days to Cover
SOPHiA GENETICS has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in SOPHiA GENETICS has recently decreased by 4.30%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
SOPHiA GENETICS does not currently pay a dividend.
Dividend Growth
SOPHiA GENETICS does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SOPH.

1.4

News and Social Media Coverage

News Sentiment
SOPHiA GENETICS has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.88% of the stock of SOPHiA GENETICS is held by insiders.
Percentage Held by Institutions
Only 36.68% of the stock of SOPHiA GENETICS is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for SOPHiA GENETICS are expected to grow in the coming year, from ($1.20) to ($0.88) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SOPHiA GENETICS is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SOPHiA GENETICS is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SOPHiA GENETICS has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharma customers worldwide. The company was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

SOPH Price History

30 days | 90 days | 365 days | Advanced Chart

SOPH Stock News Headlines

September 26, 2023 | americanbankingnews.com

SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Up 5%

September 20, 2023 | americanbankingnews.com

SOPHiA GENETICS (NASDAQ:SOPH) vs. Ignyte Acquisition (NASDAQ:IGNY) Financial Review

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 13, 2023 | finance.yahoo.com

Laboratorio Curie Expands Relationship with SOPHiA GENETICS

September 8, 2023 | msn.com

Italy’s IRCCS IRST goes live on SOPHiA GENETICS platform

September 7, 2023 | finance.yahoo.com

SOPHiA GENETICS Announces the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) is Live on the SOPHiA DDM™ Platform

August 31, 2023 | msn.com

CHU Bordeaux deploys SOPHiA DDM Platform to support cancer research

August 30, 2023 | finance.yahoo.com

CHU Bordeaux is live on SOPHiA GENETICS

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 23, 2023 | msn.com

Gustave Roussy, SOPHiA expand alliance on cancer treatment

August 22, 2023 | finance.yahoo.com

SOPHiA GENETICS Expands Relationship with Gustave Roussy

August 18, 2023 | marketwatch.com

Sophia Genetics Up 11% as Italian Hospital Expands Platform Usage

August 17, 2023 | fool.com

SOPHiA Genetics (NASDAQ: SOPH)

August 17, 2023 | finance.yahoo.com

A.O.U. San Giovanni di Dio Ruggi d'Aragona Expands Usage of SOPHiA GENETICS DDM™ Platform

August 12, 2023 | markets.businessinsider.com

J.P. Morgan Remains a Buy on SOPHiA GENETICS (SOPH)

August 9, 2023 | msn.com

Tulane University taps SOPHiA GENETICS for blood cancer research

August 8, 2023 | finance.yahoo.com

SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates

August 8, 2023 | benzinga.com

A Preview Of Sophia Genetics's Earnings

August 8, 2023 | markets.businessinsider.com

SOPHiA GENETICS SA earnings preview: what Wall Street is expecting

August 8, 2023 | msn.com

SOPHiA Genetics GAAP EPS of -$0.33 misses by $0.02, revenue of $15.1M misses by $0.14M

August 8, 2023 | finance.yahoo.com

Tulane University School of Medicine Uses SOPHiA GENETICS to Advance Research of Blood Cancers

August 8, 2023 | finance.yahoo.com

SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023

July 30, 2023 | finanznachrichten.de

SOPHiA GENETICS' SOPHiA DDM HRD Solution is Tapped by Unipath Specialty Laboratory Limited

July 25, 2023 | finance.yahoo.com

SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2023 on August 8, 2023

July 13, 2023 | finance.yahoo.com

SOPHiA GENETICS Announces Gruppo Centro Servizi Medici (CSM) is Live on the SOPHiA DDM™ Platform

July 7, 2023 | finance.yahoo.com

Centre Hospitalier de Bastia is Live on SOPHiA GENETICS

July 2, 2023 | finance.yahoo.com

SOPHiA GENETICS (NASDAQ:SOPH) swells 17% this week, taking one-year gains to 20%

See More Headlines

Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

SOPH Company Calendar

Last Earnings: 8/08/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SOPH
CUSIP: N/A
CIK: 1840706
Web: www.sophiagenetics.com
Phone: 41-21-694-1060
Fax: N/A
Employees: 466
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.33
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +161.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-87,450,000.00
Net Margins: -145.00%
Pretax Margin: -145.34%
Return on Equity: -41.11%
Return on Assets: -33.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.34
Quick Ratio: 5.17

Sales & Book Value

Annual Sales: $47.56 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.16 per share
Price / Book: 0.77

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.33

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Jurgi Camblong M.B.A. (Age 45)
Ph.D., Co-Founder, CEO & Director
Comp: $1.11M

Mr. Ross Jordan Muken B.Sc. (Age 42)
Exec. VP, CFO & COO

Mr. Abhimanyu Verma
Sr. VP & CTO

Dr. Zhenyu Xu Ph.D. (Age 40)
Exec. VP & Chief Scientific Officer

Katherine Bailon
VP of Investor Relations

Mr. Daan van Well L.L.M. (Age 49)
M.B.A., Exec. VP, Chief Legal Officer & Gen. Counsel

Mr. Kevin Puylaert
VP of Bus. Devel. & Marketing

Ms. Manuela Da Silva Valente B.A. (Age 52)
Sr. VP & Chief People Officer

Dr. Philippe Menu M.B.A. (Age 41)
M.D., Ph.D., Exec. VP, Chief Medical Officer & Chief Product Officer

Mr. Peter Casasanto
Sr. VP & Chief BioPharma Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SOPH Stock - Frequently Asked Questions

Should I buy or sell SOPHiA GENETICS stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SOPH shares.
View SOPH analyst ratings or view top-rated stocks.
What is SOPHiA GENETICS's stock price forecast for 2023?: 3 brokerages have issued 1-year target prices for SOPHiA GENETICS's shares. Their SOPH share price forecasts range from $2.00 to $11.00. On average, they expect the company's share price to reach $6.33 in the next year. This suggests a possible upside of 161.7% from the stock's current price.
View analysts price targets for SOPH or view top-rated stocks among Wall Street analysts.
How have SOPH shares performed in 2023?: SOPHiA GENETICS's stock was trading at $2.06 at the start of the year. Since then, SOPH stock has increased by 17.5% and is now trading at $2.42.
View the best growth stocks for 2023 here.
When is SOPHiA GENETICS's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our SOPH earnings forecast.
How were SOPHiA GENETICS's earnings last quarter?: SOPHiA GENETICS SA (NASDAQ:SOPH) posted its earnings results on Tuesday, August, 8th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.04. The firm earned $15.05 million during the quarter, compared to analyst estimates of $15.10 million. SOPHiA GENETICS had a negative net margin of 145.00% and a negative trailing twelve-month return on equity of 41.11%.
What guidance has SOPHiA GENETICS issued on next quarter's earnings?: SOPHiA GENETICS updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $61.83M-, compared to the consensus revenue estimate of $62.12 million.

When did SOPHiA GENETICS IPO?: (SOPH) raised $234 million in an initial public offering on Friday, July 23rd 2021. The company issued 13,000,000 shares at $17.00-$19.00 per share.
What is SOPHiA GENETICS's stock symbol?: SOPHiA GENETICS trades on the NASDAQ under the ticker symbol "SOPH."
Who are SOPHiA GENETICS's major shareholders?: SOPHiA GENETICS's stock is owned by a variety of institutional and retail investors. Top institutional investors include Credit Suisse AG (0.00%), Principal Financial Group Inc. (0.00%), Pura Vida Investments LLC (0.00%), Geode Capital Management LLC (0.00%), JPMorgan Chase & Co. (0.00%) and Meitav Investment House Ltd. (0.04%).
How do I buy shares of SOPHiA GENETICS?: Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is SOPHiA GENETICS's stock price today?: One share of SOPH stock can currently be purchased for approximately $2.42.
How many employees does SOPHiA GENETICS have?: The company employs 466 workers across the globe.
How can I contact SOPHiA GENETICS?: The official website for the company is www.sophiagenetics.com. The company can be reached via phone at 41-21-694-1060.

This page (NASDAQ:SOPH) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

SOPHiA GENETICS (SOPH) Stock Forecast, Price & News

SOPHiA GENETICS MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPH Price History

SOPH Stock News Headlines

SOPH Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

SOPH Stock - Frequently Asked Questions

Overall MarketRank^™